Lenacapavir Injection
Sponsors
Gilead Sciences, Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida, Desmond Tutu HIV Foundation
Conditions
HIVHIV I InfectionHIV InfectionHIV InfectionsHIV Pre-exposure ProphylaxisPre-Exposure Prophylaxis of HIV Infection
Phase 2
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
Active, not recruitingNCT05729568
Start: 2023-05-15End: 2029-12-31Updated: 2025-07-15
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)
Active, not recruitingNCT06101342
Start: 2023-12-13End: 2028-01-01Updated: 2026-03-02
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
Active, not recruitingNCT06101329
Start: 2023-11-17End: 2028-01-31Updated: 2025-09-23
Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)
Active, not recruitingNCT06513312
Start: 2024-10-07End: 2028-12-31Updated: 2025-09-02
Phase 3
Unknown Phase
Real World Use of Lenacapavir, as an add-on to an Optimized Background Regimen in France
RecruitingNCT06799338
Start: 2025-03-03End: 2025-12-31Target: 80Updated: 2025-05-22
ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.
Not yet recruitingNCT07390409
Start: 2026-01-29End: 2028-05-01Target: 3700Updated: 2026-02-05
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
RecruitingNCT07473778
Start: 2026-03-17End: 2029-04-01Target: 3000Updated: 2026-04-03